-

LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September

GLOUCESTER, England--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the two following September healthcare conferences in New York City:

  • Morgan Stanley 24th Annual Global Healthcare Conference on Mon., Sept. 14, from 11:30 a.m.-12:05 p.m. EDT
  • Baird 2026 Global Healthcare Conference on Tues., Sept. 15, from 11:25-11:55 a.m. EDT

Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Philip Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat at Morgan Stanley, while Ahmet Tezel, Ph.D., Chief Innovation Officer of LivaNova, will join Makatsaria and Shvartsburg at Baird.

The discussions will be available to all interested parties who register to attend the webcasts, which are accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper webcast setup. Replays will be available on the LivaNova website within 24 hours after the live presentation.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience with a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. With its registered office in the United Kingdom, approximately 3,300 employees, and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova Investor Relations and Media Contacts

+1 281-895-2382
Briana Gotlin
VP, Investor Relations
InvestorRelations@livanova.com
Jim Masilak
Director, External Communications
Corporate.Communications@livanova.com

LivaNova PLC

NASDAQ:LIVN
Details
Headquarters: London, United Kingdom
CEO: Vladimir Makatsaria
Employees: 3000
Organization: PUB
Revenues: $1.25B (2024)
Net Income: $63.2M (2024)

Release Versions
$Cashtags

Contacts

LivaNova Investor Relations and Media Contacts

+1 281-895-2382
Briana Gotlin
VP, Investor Relations
InvestorRelations@livanova.com
Jim Masilak
Director, External Communications
Corporate.Communications@livanova.com

Social Media Profiles
More News From LivaNova PLC

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

GLOUCESTER, England--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the second quarter ended June 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared to the prior-year period Second-quarter U.S. GAAP diluted earnings per share of $1.93 and adjusted diluted earnings per sh...

LivaNova to Announce Second-Quarter 2026 Results

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To lis...

LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patients with moderate to severe Obstructive Sleep Apnea (OSA) when treated with proximal hypoglossal nerve stimulation (pHGNS). The findings were presented at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societie...
Back to Newsroom